In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Adaptive workflow systems represent a significant departure from rigid, process-centric approaches. Instead of imposing a linear, step-by-step structure, teams will be able to dynamically assign and ...

Evinova’s globally-scaled digital health solutions are evidence-led, science-based and human experience-driven to serve clinical trial sponsors, clinical research organisations (CROs), clinical trial ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...

For Patrick Flanagan, CEO of Veristat, optimism will drive new financial growth.“The coming year will mark a new era of ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

The state exists to shape the future; without direction, it becomes captive to circumstance.”* **Aristotle** The government ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...